{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:31:26Z","timestamp":1791351086545,"version":"4.3.1"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,11,1]]},"DOI":"10.1093\/jac\/dku261","type":"journal-article","created":{"date-parts":[[2014,7,30]],"date-time":"2014-07-30T00:26:01Z","timestamp":1406679961000},"page":"2892-2900","source":"Crossref","is-referenced-by-count":86,"title":["Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison"],"prefix":"10.1093","volume":"69","author":[{"given":"Oliver A.","family":"Cornely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilip","family":"Nathwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ivanescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olatunji","family":"Odufowora-Sita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peny","family":"Retsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac A. O.","family":"Odeyemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,7,28]]},"reference":[{"issue":"Suppl 2","key":"key\n\t\t\t\t20170522225444_DKU261C1","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1093\/cid\/cis319","article-title":"Current status of Clostridium difficile infection epidemiology","volume":"55","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522225444_DKU261C2","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2009.02.073","article-title":"Clostridium difficile infection caused by the epidemic BI\/NAP1\/027 strain","volume":"136","year":"2009","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170522225444_DKU261C3","article-title":"Clostridium difficile Ribotyping Network for England and Northern Ireland: 2008\/09 Report","author":"HPA UK","year":"2009"},{"key":"key\n\t\t\t\t20170522225444_DKU261C4","first-page":"pii=19402","article-title":"Decrease of hypervirulent Clostridium difficile PCR ribotype 027 in the Netherlands","volume":"14","year":"2009","journal-title":"Euro Surveill"},{"key":"key\n\t\t\t\t20170522225444_DKU261C5","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1086\/592257","article-title":"Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078","volume":"47","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522225444_DKU261C6","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1086\/649011","article-title":"First report of hypervirulent strains polymerase chain reaction ribotypes 027 and 078 causing severe Clostridium difficile infection in Italy","volume":"50","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522225444_DKU261C7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhin.2010.03.025","article-title":"Infection due to C. difficile ribotype 078: first report of cases in the Republic of Ireland","volume":"75","year":"2010","journal-title":"J Hosp Infect"},{"key":"key\n\t\t\t\t20170522225444_DKU261C8","doi-asserted-by":"crossref","first-page":"c1296","DOI":"10.1136\/bmj.c1296","article-title":"Prevention and medical management of Clostridium difficile infection","volume":"340","year":"2010","journal-title":"BMJ"},{"issue":"Suppl C","key":"key\n\t\t\t\t20170522225444_DKU261C9","first-page":"5","article-title":"Clinical impact and associated costs of Clostridium difficile-associated disease","volume":"41","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170522225444_DKU261C10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/MAJ.0b013e3181e939d8","article-title":"Clostridium difficile infection","volume":"340","year":"2010","journal-title":"Am J Med Sci"},{"key":"key\n\t\t\t\t20170522225444_DKU261C11","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrmicro2164","article-title":"Clostridium difficile infection: new developments in epidemiology and pathogenesis","volume":"7","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"key\n\t\t\t\t20170522225444_DKU261C12","volume-title":"Vancomycin or Metronidazole for Treatment of Clostridium difficile Infection: Clinical and Economic Analyses","year":"2011"},{"key":"key\n\t\t\t\t20170522225444_DKU261C13","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1503\/cmaj.050978","article-title":"Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec","volume":"173","year":"2005","journal-title":"CMAJ"},{"key":"key\n\t\t\t\t20170522225444_DKU261C14","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1007\/s11605-011-1615-6","article-title":"Clostridium difficile colitis: factors associated with outcome and assessment of mortality at a national level","volume":"15","year":"2011","journal-title":"J Gastrointest Surg"},{"key":"key\n\t\t\t\t20170522225444_DKU261C15","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.mayocp.2012.07.016","article-title":"Clostridium difficile infection: new insights into management","volume":"87","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t20170522225444_DKU261C16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jinf.2009.03.010","article-title":"Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes","volume":"58","year":"2009","journal-title":"J Infect"},{"key":"key\n\t\t\t\t20170522225444_DKU261C17","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/clinids\/24.3.324","article-title":"Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial","volume":"24","year":"1997","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522225444_DKU261C18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/ndt\/15.5.571","article-title":"Clostridium difficile in patients with renal failure\u2014management of an outbreak using biotherapy","volume":"15","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20170522225444_DKU261C19","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2012.45.5899","article-title":"Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170522225444_DKU261C20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0195-6701(96)90122-X","article-title":"Financial burden of hospital-acquired Clostridium difficile infection","volume":"34","year":"1996","journal-title":"J Hosp Infect"},{"key":"key\n\t\t\t\t20170522225444_DKU261C21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2710.2000.00266.x","article-title":"Clostridium difficile-associated diarrhoea in hospitalised patients","volume":"25","year":"2000","journal-title":"J Clin Pharm Ther"},{"key":"key\n\t\t\t\t20170522225444_DKU261C22","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1378\/chest.07-0202","article-title":"Analysis of 30-day mortality for Clostridium difficile-associated disease in the ICU setting","volume":"132","year":"2007","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170522225444_DKU261C23","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1086\/338260","article-title":"Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile","volume":"34","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522225444_DKU261C24","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/jac\/39.4.537","article-title":"Health care resource utilization and antimicrobial use in elderly patients with community-acquired lower respiratory tract infection who develop Clostridium difficile-associated diarrhoea","volume":"39","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170522225444_DKU261C25","first-page":"1804","article-title":"The effect of hospital-acquired Clostridium difficile infection on in-hospital mortality","volume":"170","year":"2010","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20170522225444_DKU261C26","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(95)90439-5","article-title":"Increased length of hospital stay due to Clostridium difficile associated diarrhoea","volume":"345","year":"1995","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170522225444_DKU261C27","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1086\/588756","article-title":"Rising economic impact of Clostridium difficile-associated disease in adult hospitalized patient population","volume":"29","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key\n\t\t\t\t20170522225444_DKU261C28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jhin.2012.02.004","article-title":"Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection","volume":"81","year":"2012","journal-title":"J Hosp Infect"},{"key":"key\n\t\t\t\t20170522225444_DKU261C29","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ajg.2013.4","article-title":"Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections","volume":"108","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170522225444_DKU261C30","volume-title":"Updated Guidance on the Management and Treatment of Clostridium difficile Infection","author":"Public Health England","year":"2013"},{"key":"key\n\t\t\t\t20170522225444_DKU261C31","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/WNF.0b013e3182334b35","article-title":"Metronidazole-induced central nervous system toxicity: a systematic review","volume":"34","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"key\n\t\t\t\t20170522225444_DKU261C32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2012.01.004","article-title":"Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence","volume":"40","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20170522225444_DKU261C33","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1128\/AAC.48.6.2280-2282.2004","article-title":"In vitro activity of OPT-80 against Clostridium difficile","volume":"48","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522225444_DKU261C34","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1128\/AAC.48.11.4430-4434.2004","article-title":"Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species","volume":"48","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522225444_DKU261C35","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1128\/AAC.48.12.4898-4902.2004","article-title":"In vitro activities of OPT-80 and comparator drugs against intestinal bacteria","volume":"48","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522225444_DKU261C36","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1128\/AAC.01623-06","article-title":"In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004","volume":"51","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522225444_DKU261C37","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1128\/AAC.01045-07","article-title":"Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses","volume":"52","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522225444_DKU261C38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/AAC.01443-07","article-title":"OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection","volume":"53","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522225444_DKU261C39","author":"NDC Indirect Comparison Checklist"},{"key":"key\n\t\t\t\t20170522225444_DKU261C40","author":"National Institute for Health and Care Excellence. Systematic and Other Reviews: Terms and Definitions used by UK Organisations and Selected Databases"},{"key":"key\n\t\t\t\t20170522225444_DKU261C41","author":"Systematic Reviews"},{"key":"key\n\t\t\t\t20170522225444_DKU261C42","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1128\/AAC.00605-12","article-title":"Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea","volume":"56","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522225444_DKU261C43","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","year":"2003","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20170522225444_DKU261C44","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"key\n\t\t\t\t20170522225444_DKU261C45","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1742-1241.2009.02072.x","article-title":"Indirect comparisons of treatments based on systematic reviews of randomised controlled trials","volume":"63","year":"2009","journal-title":"Int J Clin Pract"},{"key":"key\n\t\t\t\t20170522225444_DKU261C46","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","article-title":"Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses","volume":"326","year":"2003","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20170522225444_DKU261C47","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20170522225444_DKU261C48","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170522225444_DKU261C49","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1086\/588293","article-title":"Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin","volume":"47","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522225444_DKU261C50","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1086\/501553","article-title":"Recurrent Clostridium difficile disease: epidemiology and clinical characteristics","volume":"20","year":"1999","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key\n\t\t\t\t20170522225444_DKU261C51","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/j.1572-0241.2002.05839.x","article-title":"Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease","volume":"97","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170522225444_DKU261C52","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1111\/j.1572-0241.1998.00541.x","article-title":"Clostridium difficile colitis: factors influencing treatment failure and relapse\u2014a prospective evaluation","volume":"93","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170522225444_DKU261C53","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jhin.2009.11.002","article-title":"Continuing diarrhoea after ten days of oral metronidazole or oral vancomycin for presumed, hospital-acquired Clostridium difficile colitis in elderly hospital patients","volume":"74","year":"2010","journal-title":"J Hosp Infect"},{"key":"key\n\t\t\t\t20170522225444_DKU261C54","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1086\/430315","article-title":"Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada","volume":"40","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522225444_DKU261C55","first-page":"913","article-title":"Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea","volume":"9","year":"2008","journal-title":"Curr Opin Investig Drugs"},{"key":"key\n\t\t\t\t20170522225444_DKU261C56","first-page":"1043","article-title":"Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis","volume":"2","year":"1983","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170522225444_DKU261C57","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/clinids\/22.5.813","article-title":"Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea","volume":"22","year":"1996","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522225444_DKU261C58","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","article-title":"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity","volume":"45","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522225444_DKU261C59","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1128\/AAC.00476-08","article-title":"In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile","volume":"52","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522225444_DKU261C60","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1093\/jac\/dku257","article-title":"Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection","volume":"69","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170522225444_DKU261C61","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.anaerobe.2009.12.002","article-title":"Bactericidal activity of telavancin, vancomycin and metronidazole against Clostridium difficile","volume":"16","year":"2010","journal-title":"Anaerobe"},{"key":"key\n\t\t\t\t20170522225444_DKU261C62","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1128\/AAC.00104-11","article-title":"Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile","volume":"55","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522225444_DKU261C63","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1017\/S0266462308080240","article-title":"Direct versus indirect comparisons: a summary of the evidence","volume":"24","year":"2008","journal-title":"Int J Technol Assess Health Care"},{"key":"key\n\t\t\t\t20170522225444_DKU261C64","doi-asserted-by":"crossref","first-page":"e11054","DOI":"10.1371\/journal.pone.0011054","article-title":"Indirect comparisons: a review of reporting and methodological quality","volume":"5","year":"2010","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170522225444_DKU261C65","doi-asserted-by":"crossref","first-page":"529","DOI":"10.4065\/81.4.529","article-title":"Vancomycin-resistant enterococci: colonization, infection, detection, and treatment","volume":"81","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t20170522225444_DKU261C66","author":"Flagyl 200 mg Tablets (Summary of Product Characteristics)"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20170522225444_DKU261C67","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1093\/cid\/cis499","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials","volume":"55","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"issue 9","key":"key\n\t\t\t\t20170522225444_DKU261C68","first-page":"CD004610","article-title":"Antibiotic treatment for Clostridium difficile-associated diarrhea in adults","year":"2011","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T02:34:31Z","timestamp":1649817271000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dku261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,28]]},"references-count":68,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2014,7,28]]},"published-print":{"date-parts":[[2014,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dku261","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,28]]}}}